Flebogamma 5% DIF Batch Recalled in Israel Over Allergic Reactions
Translated & summarized from Ministry of Health by baba
Medici Medical is voluntarily recalling batch G04K098131 of the Flebogamma 5% DIF 200ml infusion product in Israel due to an increased number of hypersensitivity reactions. The Ministry of Health is involved in the recall, which is a Level II action affecting customers, pharmacies, and hospitals. Alternative treatments are available, and other batches of the drug remain safe for use.
The story in 5 lines · by baba
- Medici Medical is recalling Flebogamma 5% DIF batch G04K098131 in Israel due to hypersensitivity reactions.
- The recall was initiated in cooperation with Israel's Ministry of Health.
- An unusually high frequency of hypersensitivity reactions was reported from this specific batch.
- Alternative treatments are available, and other batches of the drug are unaffected.
- The recall is a Level II action involving returns from customers, pharmacies, and hospitals.
Medici Medical, the Israeli distributor of the Flebogamma 5% DIF 200ml infusion product, has initiated a voluntary recall of a specific batch, G04K098131. This action, taken in coordination with the Ministry of Health, follows reports of an unusually high frequency of hypersensitivity reactions among patients treated with this particular batch. As a precautionary measure, and given the availability of alternative treatments, all remaining stock of this batch is to be returned. The recall is classified as Level II, involving returns from customers, pharmacies, hospital clinics, and commercial establishments. Healthcare providers are instructed to immediately cease dispensing the affected batch, quarantine the items, and return them to the Soussana trading company for credit. Medici Medical has provided contact information for logistical inquiries: Rotem Tzarfati in Supply Chain at 052-5391122 and Yaron Hasid, QP, at 052-9525913. Other batches of the drug available in Israel are not affected by this recall and can be used as normal.
Mentioned
